Skip to main content

Table 3 Effect of the total mg/kg dose administered on the risk of Plasmodium vivax recurrence between days 7 and 90 in patients with information on the total mg/kg dose administered

From: Effect of adherence to primaquine on the risk of Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis

Adherence by total mg/kg dose administered

Overall risk of recurrence between days 7 and 90

Risk of recurrence between days 7 and 56

Risk of recurrence between days 56 and 90

Number of recurrences (Number of patients) †

Adjusted HR* (95% CI)

p-value

Number of recurrences (Number of patients)

Adjusted HR* (95% CI)

p-value

Number of recurrences (Number of patients)

Adjusted HR* (95% CI)

p-value

 ≥ 90%

127 (3231)

Ref.

.

49 (691)

Ref.

.

78 (2540)

Ref.

.

 > 50- < 90%

10 (81)

3.2 (1.5–6.7)

0.003

2 (38)

1.11 (0.3–4.8)

0.884

8 (43)

6.0 (2.6–13.9)

 < 0.001

 ≤ 50%

16 (311)

7.6 (1.9–30.0)

0.004

14 (253)

10.1 (1.9–52.5)

0.006

2 (58)

3.3 (0.3–38.6)

0.336

  1. HR: hazard ratio, 95% CI: 95% confidence interval
  2. * Adjusted for age, sex, baseline parasitaemia, and study site as a random effect (a detailed result is presented in Additional file 1: Table S10)
  3. Data were missing for sex (one patient), and baseline parasitaemia (49 patients)